Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no.
Investment analysts at StockNews.com initiated coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a research note issued on Monday. The firm set a “sell” rating on the stock. Advaxis Price Performance About Advaxis (Get Rating) Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) […]
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid
Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose.